CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for F3 Platform Biologics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

F3 Platform Biologics Inc
1200 Ashwood Pkwy, Suite 155
Phone: (678) 235-4396p:678 235-4396 ATLANTA, GA  30338  United States Fax: (302) 655-5049f:302 655-5049
Business Summary
F3 Platform Biologics, Inc. is a United States-based biopharmaceutical company. The Company is focused on the research, clinical development, and ultimate commercialization of amifostine. Amifostine repair and protects against human cell mutation and destruction, as well as radiation-induced genomic damage and instability (RIGDI), a precursor to carcinogenesis, which occurs when human cells are exposed to low doses of ionizing radiation, such as those present in computed tomography scans (CT scans). The Company’s product candidate, AmiGuard CT, is an injectable formulation of low dose amifostine intended to protect patients at the cellular level from harmful effects of low doses of ionizing radiation, especially RIGDI. Its BioGlena (Beta-1,3-glucan) is a biological response modifier targeted at boosting the immune system in both people and animals by stimulating the activity of white blood cells. Beta Glucans act as immunomodulators, priming immune cells to tackle tumorous cells.
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202312/31/2022YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Holger A.Liepmann 71
Chief Executive Officer Jonathan E.Peskoff 50 1/1/2021 1/1/2017
Director DanielCourchesne 57 10/4/2019 10/4/2019
Director Bernardus N.Machielse 62
Director Linda J.Peters 46

General Information
Outstanding Shares: 69,364,664 (As of 3/31/2023)
Federal Tax Id: 831243304
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, October 30, 2024